Clinical trial with arginine tidiacicate in symptomatic chronic persistent hepatitis.

  • Suzanne Rizzo
  • Published 1986 in
    International journal of clinical pharmacology…


In a double-blind study, 50 patients with chronic persistent hepatitis were assigned at random to two treatment groups. One group was given arginine tidiacicate (ATCA) at the dose of 400 mg tablets three times a day and the other given a placebo, both for 30 days. The group of patients receiving ATCA showed a clear-cut improvement of subjective symptoms and… (More)


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics